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Abstract
Many clinicians lack experience in managing trigeminal autonomic cephalalgias (TACs) in 
pregnancy and lactation. In addition to cluster headache, TACs include hemicrania con-
tinua, paroxysmal hemicrania, and short- lasting unilateral neuralgiform headache with 
conjunctival injection and tearing/autonomic symptoms (SUNCT/SUNA). Treating these 
rare, severe headache conditions often requires off- label drugs that have uncertain tera-
togenic potential. In the last few years, several new treatment options and safety docu-
mentation have emerged, but clinical guidelines are lacking. This narrative review aimed 
to provide an updated clinical guide and good clinical practice recommendations for the 
management of these debilitating headache disorders in pregnancy and lactation.
K E Y W O R D S
breastfeeding, headache, hemicrania continua, Horton's headache, paroxysmal hemicrania, 
pregnancy, SUNCT, trigeminal autonomic cephalalgias
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INTRODUC TION
Trigeminal autonomic cephalalgias (TACs) are a group of uncom-
mon, but extremely painful primary headaches. TACs include 
cluster headache, hemicrania continua, paroxysmal hemicrania, 
and short- lasting, unilateral neuralgiform headache attacks with 
conjunctival injection and tearing/cranial autonomic symptoms 
(SUNCT/SUNA) [1]. These disorders share similar clinical features 
but differ in frequency, duration, triggers and treatment (Table 1) 
[2]. All TACs present with unilateral, intense pain in the area in-
nervated by the first branch of the trigeminal nerve. Ipsilateral, 
parasympathetic cranial autonomic features comprise part of the 
clinical spectrum during attacks (Table 1). Patients with cluster 
headache and paroxysmal hemicrania can experience the disor-
der in an episodic form, with bouts of attacks lasting from weeks 
to months. However, some patients can develop a chronic form, 
without long, attack- free periods.
Most prophylactic drugs for TACs are prescribed off- label, which 
places extra responsibility on the treating physician [3]. Few non-
pharmacological options with documented effects are available. 
Managing TACs in pregnant or breastfeeding women is often chal-
lenging. Few clinical guidelines and reviews focus specifically on 
TACs during pregnancy and lactation [4- 7]. In the last few years, sev-
eral new treatment options for TACs have emerged and the safety 
documentation has improved for the use of several drugs during 
pregnancy and lactation. Therefore, we aimed to perform an up-
dated, clinically useful review on the management of cluster head-
ache and other TACs during pregnancy and lactation and to provide 
good clinical practice recommendations (Table 2).
METHODS
Search strategy
We performed a literature search in Medline and Embase with the 
keywords: “cluster headache”, “trigeminal autonomic cephalalgias”, 
SUNCT, hemicrania continua, paroxysmal hemicrania and “pregnancy”, 
“pregnancy outcome”, “birth defects”, “congenital malformations”, 
“breastfeeding”, and “lactation”, combined with individual drugs com-
monly used to treat TAC (Table 3). Medical Subject Heading (MeSH) 
terms were used, when possible. For each relevant paper, the bibliog-
raphy was scrutinized for additional citations. Only studies in humans 
published in English or Scandinavian languages were included. The 
time period ranged from database inception to May 2020. We con-
sulted the headache treatment guidelines from the American Academy 
of Neurology and the American Headache Society [8], the Canadian 
Headache Society [9,10], the British Association for the Study of 
Headache [11] and the European Academy of Neurology (EAN, pre-
viously EFNS) [12]. Further, we consulted the National Library of 
Medicine's Drugs and Lactation Database (LactMed), UpToDate, 
Reprotox, the Royal College of Obstetricians and Gynecologists, and 
the National Institute for Health and Care and Excellence (NICE) rec-
ommendations [6,13,14,15,16]. Finally, the authors' clinical experi-
ences were included.
CLINIC AL PIC TURE AND EPIDEMIOLOGY 
OF TAC S
Table 1 summarizes the main characteristics of TACs. Below is a brief 
overview of what is known about these conditions among pregnant 
and lactating women and among women of childbearing age.
Approximately 45% of women report that cluster headaches 
started in their twenties or at a younger age [17]. Due to the in-
creasing age of pregnant women, it is likely that the occurrence 
of this condition among childbearing women is growing. Women 
experience the chronic, unremitting form of cluster headache more 
often than men [18]. Although patients who experience migraines 
often improve during pregnancy, cluster headache is less sensitive 
to hormonal changes [3]. In one study of women who experienced 
cluster headaches, 52% reported improvement, 35% reported no 
change, and 13% reported worsening of the condition during preg-
nancy [17]. Cluster headaches can have large implications for family 
life. Several studies have found that women who experience their 
first attack before their first gestation typically have fewer chil-
dren than those that were already mothers at the time of clinical 
onset [19,20]. In one study, approximately 60% of female patients 
with cluster headaches did not have children after the point of di-
agnosis. Among these women, 8% feared that the attacks would 
prevent them from taking care of a child, and 4% were afraid to 
pass the disorder on [17]. In addition to the effect on family plan-
ning, this disorder can impact social functioning and quality of life. 
It increases the risk of major depression, and over 50% of women 
with cluster headaches reported suicidal thoughts [21]. Compared 
to men, women more often report violence during attacks, such as 
hitting themselves or hitting objects [17]. They are also more likely 
to have migrainous features, such as photophobia and nausea, or 
comorbid migraine [17,18]. Some studies have shown that a correct 
diagnosis was delayed more often in women compared to men, and 
women were more likely to be misdiagnosed [17,18,22].
The frequency of paroxysmal hemicrania is two- to threefold 
higher among women than among men [23,24]. It is currently un-
known how paroxysmal hemicranias might affect pregnancy, and 
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vice versa. In a small case series of chronic paroxysmal hemicranias, 
50% of women reported that the disorder started in the postpartum 
period. Among patients who developed the disorder before preg-
nancy, 90% reported that pregnancy improved the condition, but 
that attacks started again immediately after birth [24].
Women are diagnosed with hemicranias continua two to three 
times as often as men [25]. The true prevalence is unknown, but the 
disorder is probably the most common TAC, after cluster headache 
[26]. It is currently unknown whether the frequency and/or severity 
changes during pregnancy.
There are probably fewer women than men with SUNCT/SUNA. 
The disorder sometimes occurs during pregnancy [27], but probably 
less often than the other TACs because most patients develop these 
disorders in their forties.
MANAGEMENT
Table 2 summarizes the good clinical practice recommendations for 
caring for women with TACs.
Prepregnancy counseling
Physicians need to ask all women of childbearing age with TACs 
early and repeatedly about family plans. Preferably, prophylactic 
treatment should be discontinued at least five half- lives before preg-
nancy to avoid teratogenicity [28]. However, unplanned pregnancies 
occur in 45% of women with chronic health conditions [29]. Hence, 
even when no pregnancy plans are imminent, the treatment should 
be as compatible with pregnancy as possible. It might take time to 
find an effective treatment that has low risk potential for a future 
pregnancy [3] (Tables 2 and 3). It is important to titrate to the low-
est effective dose to ensure a good balance between controlling 
attacks and potential side effects. Women who use drugs that are 
potentially harmful to the fetus (red and orange boxes in Table 3), 
must be repeatedly informed of the risks. When using teratogenic 
drugs (red boxes in Table 3), women should be offered effective 
contraceptives (Table 2). Clinicians should be aware that antiseizure 
drugs such as topiramate and lamotrigine commonly used in TAC 
prophylaxis might interact with hormonal contraception [30]. All 
women of childbearing age using antiseizure drugs should also take 
TA B L E  1  Epidemiological and clinical features of different trigeminal autonomic cephalalgias
Cluster headache
Paroxysmal 
hemicrania Hemicrania continua SUNCT/SUNA
Epidemiology
Prevalence 100:100,000 20– 50:100,000 50:100,000 50– 100:100,000
Ratio female/male 1:3 2– 3:1 2:1 1:1.5
Typical age of onset 20– 40 years 30– 40 years 30– 50 years 40– 70 years
Relationship pregnancy ~1 out of 2 improve, ~1 out 
of 8 worsen
May start postpartum Unknown Unknown
Attacks
Duration (min) 15– 180 min (typically 
100 min)
2– 30 min (typically 
15 min)
Continuous >3 months, with 
exacerbations daily or less
1– 600 s (typically 
1 min)
Frequency (per day) Once every other day, 
up to 8 times per day 
(typically 3– 4 per day)
>5 per day (typically 
10 per day)
Continuous >3 months >1 per day or more 
(typically 60 per 
day)
Quality of pain Sharp, stabbing, throbbing Sharp, stabbing, 
throbbing




Severity of pain Severe to very severe Severe Baseline any severity, flares 
moderate to severe
Moderate to severe
Autonomic features at the 
side of the pain:
Red, running eye, stuffed 
running nose, swollen 
or dropping eyelid, 
facial sweating, small 
pupil
Yes Yes Yes Yes
Restlessness or agitation Yes Yes Yes No
Circadian pattern >80% Rare Rare Rare
Treatment
Oxygen Yes No No No
Triptans Yes No No No
Indomethacin No Yes Yes No
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0.4 mg folic acid supplements, regardless of pregnancy plans [31]. 
Moreover, many authors recommend that women using antiseizure 
drugs should increase the dose of folic acid to at least 1 mg before 
and during pregnancy [31].
For some patients with TACs, the headache condition is not 
manageable in pregnancy without prophylactic drugs. When plan-
ning pregnancy, patients must be educated about the off- label use of 
most prophylactic drugs for TACs. They should be informed that lim-
ited evidence is available regarding the efficacy and safety of these 
drugs during pregnancy and lactation [7,32]. It may be beneficial to 
include the next of kin in these conversations. Individualized, sen-
sitive and honest information sets realistic expectations and allows 
patients to make educated decisions. It is our experience that fear of 
teratogenicity frequently leads to abrupt discontinuation of prophy-
lactic drugs, which may induce headache worsening. This situation 
can potentially result in an increase in use of acute drugs, stress, 
nutritional deficiency, social isolation, and depressive symptoms. In 
turn, these factors are associated with adverse pregnancy outcome 
[33]. For some women, continuation of a prophylactic substance po-
tentially harmful for the fetus might be the right decision.
Other topics in prepregnancy consultations include fertility is-
sues and heritability. In vitro fertilization often worsens headaches 
in women susceptible to migraines [34], but it remains unknown how 
such hormonal treatments affect cluster headache or other TACs. 
Genetic epidemiological surveys have indicated that first- degree 
relatives are five to 18 times more likely to develop cluster head-
aches than the general population [35]. However, because the 
prevalence of cluster headache is low, the absolute risk of a child 
inheriting the disorder is small.
Follow- up during pregnancy
Pregnant women that need treatment for cluster headache in preg-
nancy should receive specialist advice [14]. Based on our clinical 
experiences, patients that have frequent attacks during pregnancy 
require close follow- up to adjust the drug doses and to handle co-
morbid psychosocial challenges that could be worsened or triggered 
by the pregnancy. Some women worry that the drugs or the attacks 
might harm the unborn child. In our opinion, it is preferential for pa-
tients to be followed by a coordinated, cross- disciplinary team that 
includes a headache specialist, a headache nurse, and other person-
nel, based on the individual patient's needs. It is also important to 
maintain close collaboration with the patient's general practitioner, 
midwife and obstetrician. Due to the rarity of these disorders, the 
obstetrics department might need information about what to expect 
if attacks occur before or during delivery, and how they should be 
handled. Attack- free patients who are taking prophylactic drugs 
should also be offered neurological follow- up during pregnancy. 
Serum concentrations of some prophylactic drugs, such as lithium 
TA B L E  2  Best clinical practice recommendations for women with trigeminal autonomic disorders (TACs) before, during and after 
pregnancy (reference [6,14,15,16,28,31,55,60,69,74]).
1 Discuss pregnancy plans with women of childbearing age with TACs well advance of conception
2 Choose effective drugs with good pregnancy safety profile in women of childbearing age with TACs regardless of pregnancy plans
3 Women on teratogenic drugs should use effective contraception
4 If possible, discontinue prophylactic drugs 5 half- lives before pregnancy [28]
5 Women needing treatment for TACs in pregnancy should be advised by a specialist [14]
6 Collaborate with her family physician, midwife, and obstetrician during pregnancy. Consider a plan for delivery and postpartum that 
describes how to prevent and handle attacks*
7 Consider screening for depression and anxiety during and after pregnancy [74]
8 Women of childbearing age on antiseizure drugs should use 0.4 mg folate supplement. Consider high dose folate supplement (1– 5 mg) if 
antiseizure drugs are inevitable during pregnancy [31]
9 For acute treatment of cluster headache, oxygen inhalation is first choice in pregnancy. If not sufficient, try intranasal triptans, intranasal 
lidocaine and/or or sumatriptan sc [6,15]
10 Transitional prophylaxis with per oral steroids or greater occipital nerve blockade can be used in the lowest dose and duration necessary 
among pregnant and breastfeeding women [16]
11 Verapamil is first choice if continuous prophylaxis is needed in cluster headache during pregnancy, if possible, avoid in third trimester [16]
12 Do not prescribe valproate to women of childbearing age with TACs during pregnancy unless everything else is ineffective. If used, a 
pregnancy prevention plan must be in place [60]
13 Avoid lithium during pregnancy and lactation unless everything else is ineffective [55]
14 If use during pregnancy cannot be avoided, check needs for dose adjustment of topiramate, lamotrigine, and lithium by measuring serum 
concentrations before, during and after pregnancy [31,55]
15 Avoid indomethacin in women trying to conceive and after the first trimester [69]. Use with caution in the first trimester [74]
16 Apart from lithium, most drugs used for TACs are probably compatible with breastfeeding if the child is full born and healthy, and the 
mother can adequately observe the infant for side effects [15]. Galcanezumab could be considered after the first postpartum week
Note: The recommendations are based on published literature, clinical guidelines, summary of product characteristic (SmPC) and our own clinical 
experience (marked with*).
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and lamotrigine, often decline in the gestational period [31,36]. If 
the physician and the woman decide that the benefit of continuing 
these medications outweigh the potential risk for the child (Table 3), 
then serum concentrations should be monitored, and doses adjusted 
accordingly. Furthermore, patients taking drugs with teratogenic po-
tential (red boxes in Table 3) during pregnancy might need referrals 
to additional obstetric follow- ups, including ultrasound scans for de-
tecting structural anomalies or fetal complications [37].
For women with frequent, disabling attacks, delivery and care of 
the newborn can be challenging. In the third trimester, planning the 
delivery and postpartum period together with the woman may re-
duce maternal stress. The plan should optimally include the mode of 
delivery, anesthesia during delivery, a medication plan, breastfeed-
ing advice, and newborn care advice. Some women might need extra 
support to care for the infant, both in the maternity ward and after 
leaving the hospital. Lack of sleep or alterations in diurnal rhythms 
may, for example, trigger attacks [38]. Practical solutions should be 
discussed with the woman and her next of kin, and if needed, with 
community health personnel.
Follow- up in the postpartum period
In most situations, the benefits of breastfeeding outweigh the risk 
of side effects in breastfed infants (Table 3). The risk of side effects 
is highest for infants under 3 months old, due to immature liver 
and kidney functions, particularly if the infant was born premature, 
small- for- gestational age, or ill [39]. The side effects most observed 
in infants of mothers that use drugs for cluster headache and TACs 
include diarrhea, drowsiness, irritability, inadequate weight gain, 
and delayed developmental milestones (Table 3). Few side effects 
have been reported in infants after 3 months of age. When giv-
ing breastfeeding advice, the clinician should consider the ability 
of the parent to monitor and detect these symptoms. The risk−ben-
efit balance of breastfeeding versus not breastfeeding may differ in 
women with headache bouts compared to women with chronic and 
severe forms of the disorders. The women should be assured that 
not breastfeeding may also be a sensible and safe choice.
CLUSTER HE ADACHE
Attack treatment
In nonpregnant women with cluster headache, the first choice of at-
tack treatment is oxygen inhalation and subcutaneous or intranasal 
sumatriptan or intranasal zolmitriptan [40,41]. Approximately 70% 
of female patients respond to these strategies [7]. Other acute treat-
ments that are in use, but have little or no clear evidence of efficacy, 
include nasal application of lidocaine, noninvasive vagal stimulation 
and octreotide [2]. Guidelines do not recommend opioid treatment 
for primary headache disorders [40,41], and first trimester use is as-
sociated with a slightly increased risk of oral clefts [42].
During pregnancy and lactation, oxygen inhalation is the first- 
line treatment, and it is considered safe for both the mother and 
child [7].
Several large observational studies have investigated the safety 
of sumatriptan and zolmitriptan during pregnancy. They showed that 
these drugs did not increase the risk of major congenital malforma-
tions in the infant, but caution when using repeated doses is still 
warranted as triptans have vasoconstrictor effects [5,43,44]. In con-
trast to patients with migraine, patients with cluster headache might 
require multiple administrations each day. We therefore advise using 
the nasal sprays if these are sufficient because they provide signifi-
cantly less drug exposure than an injection [28,45]. Sumatriptan is 
considered safe to use during breastfeeding, because the exposure 
to the infant is very low [7].
Limited evidence exists for the safety of intranasal applications 
of lidocaine during pregnancy, but extensive experience with subcu-
taneous lidocaine administration for local anesthesia has shown no 
significant adverse reproductive or teratogenic effects and is safe to 
use during breastfeeding [3,6,15].
Noninvasive vagal nerve stimulation on the neck can serve as both 
an acute and prophylactic treatment for cluster headache, but it has not 
been tested in pregnancy. Vagal nerve fibers supply the myometrium, 
vasculature, and pelvic ganglia, therefore, this treatment might theo-
retically affect the uterus [46]; moreover, vagal stimulation can have 
hormonal effects [47]. Among pregnant women with epilepsy, those 
who received vagal nerve stimulation required slightly more obstetric 
interventions, but rates of congenital malformations in such patients 
did not increase compared to patients who did not receive vagal stim-
ulation [48]. Vagal nerve stimulation can be used in lactating women.
Prophylactic treatment
Transitional prophylaxis with steroids is used for treating bouts 
of cluster headache and episodes of worsening in chronic clus-
ter headache [3]. Most clinicians administer oral prednisolone 
or methylprednisolone, or for greater occipital nerve infiltra-
tion, a mixture of local anesthesia and injectable glucocorticoids. 
Unfortunately, many patients experience relapse when tapering 
off the treatment. These patients require maintenance prophy-
lactic treatment. Traditionally, the first- line option is verapamil, 
the second- line options are topiramate and lithium, and the third- 
line options are valproate, melatonin, baclofen, and gabapentin. 
In 2019, the US Food and Drug Administration (FDA) approved 
galcanezumab, an antibody against monoclonal calcitonin gene- 
related peptide (CGRP), for episodic cluster headache. In addition, 
evidence of efficacy is accumulating for sphenopalatine ganglion 
(SPG) stimulation [49]. Evidence of efficacy is uncertain for occipi-
tal nerve stimulation or deep brain stimulation [50]. Additionally, 
a pilot study showed that a botulinum toxin block of the SPG had 
potential for treating chronic cluster headache [51]. A randomized 
controlled trial (NCT03944876) is currently recruiting patients to 
determine the efficacy of blocking the SPG [52].
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During pregnancy, short- term transitional prophylaxis with oral 
steroids is unlikely to cause serious adverse effects. Glucocorticoids 
have been found to be teratogenic in animals. In humans, some stud-
ies have found an association with oral clefts [32]. However, the 
majority of studies do not suggest that use of oral glucocorticoids 
increase the risk of congenital anomalies overall [16]. Late pregnancy 
high- dose steroid use can induce a mild, transitional suppression of 
adrenocortical function in the newborn child. Glucocorticoids trans-
fer into breast milk, but short- term oral use is likely to be safe during 
breastfeeding [15,16].
It remains unclear whether a greater occipital nerve injection of 
steroids for transitional prophylaxis might affect the fetus less than 
oral steroid administration. Injectable steroids in the first trimes-
ter have not been well studied. In randomized trials on methods to 
prevent preterm birth, betamethasone injections did not adversely 
affect mortality or neurodevelopmental measures compared to pla-
cebo [53]. Greater occipital nerve blocks with steroids are therefore 
most likely safe in pregnancy [28]. Moreover, local betamethasone 
injections have not had harmful effects on breastfeeding children, 
but milk production might be temporarily reduced [15].
In small observational studies in patients with cardiovascular dis-
orders, and in a systematic review, verapamil was not associated with 
an increased risk of fetal malformations [32,54]. However, patients 
with cluster headache often use higher verapamil doses than other 
patient groups; thus, the generalizability of published results to this 
group of patients remains uncertain [2]. Moreover, some studies have 
shown lower birth weight and fetal loss, but these effects could not 
be separated from the effect of the underlying maternal/fetal illness 
and comedication [16]. Verapamil is detectable in breast milk, but it is 
unlikely to cause adverse effects in the breastfed child [16].
Lithium crosses the placenta easily and exposure to the fetus is 
considerable. The use of lithium during pregnancy has been associ-
ated with a range of maternal and fetal complications [36,55]. Some, 
but not all, studies have found that lithium was associated with an 
increased risk of fetal death and congenital malformations, particu-
larly cardiac anomalies [36]. However, the long- term psychomotor 
development of the child appeared to be normal [36]. Considerable 
amounts of lithium pass into breast milk, and side effects have been 
reported [15]. Lithium is generally considered contraindicated in 
pregnancy and breastfeeding. However, it may be the only efficient 
option in a few women with severe disorder, because other, less 
harmful measures are ineffective (Table 3). For these women, clini-
cians should consider referral for fetal echocardiography and moni-
tor the lithium concentration frequently [36].
In utero exposure to topiramate is associated with an increased 
risk of congenital malformation and growth restriction [31,32] and 
possibly fetal death/spontaneous abortions [32]. Patients with clus-
ter headache should not use topiramate during pregnancy unless 
other options are ineffective (Table 3). If topiramate use cannot be 
avoided, clinicians should monitor serum concentrations because 
they often drop during pregnancy and subsequently increase after 
delivery. During lactation, less than 200 mg/daily topiramate results 
in insignificant serum levels in the breastfed infant. Thus, topiramate 
is considered compatible with breastfeeding of healthy full- term 
children, after the newborn period [15].
Galcanezumab, an anti- CGRP antibody, has not been inves-
tigated for safety during human pregnancy. Animal studies have 
not reported adverse reproductive toxic effects [56]. Human im-
munoglobulin (IgG) is known to cross the placental barrier, but no 
specific safety issues have so far emerged with use of anti- GCRP 
antibodies in pregnancy [57]. As real- life data are still limited, it 
is preferable to avoid the use of galcanezumab during pregnancy 
as a precautionary measure. This is in line with the recommenda-
tion in the summary of product characteristics [58]. Experimental 
studies have shown that CGRP- dependent vascular relaxation 
was compromised in preeclamptic pregnancies, and there is a the-
oretical risk that CGRP antibodies may cause placental vascular 
impairment [59]. We lack information on the effect of anti- CGRP 
antibodies on breastfeeding. Human IgG is excreted in breast milk 
during the first days after birth, but the concentrations sharply 
decline soon afterwards. Therefore, after this period, due to poor 
transfer and low oral bioavailability, anti- CGRP antibodies are 
unlikely to cause adverse effects in a full- term healthy child. No 
safety issues have emerged for galcanzumab in lactation so far 
[57]. If clinically needed, galcanezumab could be considered in 
breastfeeding women after the first postpartum week.
Valproate is related to approximately 11% of congenital mal-
formations. Studies have shown that compared to unexposed chil-
dren, 30– 40% of children exposed to valproate have developmental 
problems, including lower IQ, and autism [31,60]. Therefore, the 
European Medicines Agency has issued warnings against the use of 
valproate in women of childbearing age, unless all other options are 
ineffective. Moreover, they imposed a pregnancy prevention plan 
to avoid pregnancy exposures [60]. Women with no other options 
must use safe contraception and be very well informed. Valproate 
must be discontinued when a pregnancy occurs unexpectedly. The 
transfer of valproate to breastmilk is very low; thus, it can be used 
during lactation [61]. However, breastfeeding women must use ef-
fective contraceptives to avoid pregnancy.
Most observational studies on gabapentin have found no signif-
icant increases in congenital malformations or pregnancy complica-
tions [31]. Among women who previously responded to gabapentin, 
it might be an acceptable treatment option when prophylaxis during 
pregnancy is needed. No studies have reported side effects among 
breastfed infants of women using gabapentin, but safety documen-
tation is limited [15].
Theoretically, exogenous use of melatonin could interfere with 
the natural wake– sleep cycle of the unborn and breastfeeding 
child, but no data are available to support or refute this concern 
[5,15].
Surgical interventions
Two case reports describe four successful pregnancies among 
two women who received occipital nerve stimulation during their 
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pregnancies for cluster headache and chronic paroxysmal hemi-
crania [62,63]. No data are available on the safety of SPG stimu-
lation during pregnancy. We do not recommend these invasive 
procedures during pregnancy because they require general anes-
thesia and require an observation and planning period to docu-
ment a refractory situation that is unlikely to be compatible with 
the duration of a pregnancy. However, among patients who had 
stimulators before a pregnancy, there is no reason to believe that 
the local electrical stimulation should pose any risk. We do not 
recommend botulinum toxin blockade of the SPG in pregnancy. 
Even though studies of botulinum toxin administered for other in-
dications have not shown harmful effects in pregnancy and lacta-
tion [64], the SPG- blocking procedure has not been performed in 
pregnant women.
PAROX YSMAL HEMICR ANIA
Paroxysmal hemicrania attacks are generally so short that acute 
drugs cannot provide benefit [2]. In the nonpregnant population, 
prophylactic indomethacin is the standard treatment. For patients 
who cannot tolerate this treatment due to gastrointestinal side ef-
fects, clinical guidelines propose selective cyclooxygenase- 2 (COX- 
2) inhibitors, such as celecoxib, or treatments that are effective in 
other TACs, such as verapamil, topiramate, or SPG- and greater oc-
cipital nerve blocks [2]. Unfortunately, the response rates to these 
treatments are highly variable [65,66].
In the pregnant population, most but not all studies found that 
indomethacin did not reduce fertility, increase the risk of fetal loss, 
or increase the risk of malformations [67,68]. However, after the 
first trimester, indomethacin can cause restriction or premature clo-
sure of the ductus arteriosus, which can lead to pulmonary hyper-
tension and neonatal death [68]. Case reports have also found that 
indomethacin was associated with preeclampsia deterioration, oli-
gohydramnios, renal impairment, necrotizing enterocolitis, periven-
tricular leucomalacia and intracranial hemorrhage [32,68]. The FDA 
has issued a warning against use of nonsteroidal anti- inflammatory 
drugs after week 20 of pregnancy due to risk of oligohydramnios and 
fetal renal failure [69]. COX- 2 inhibitors appeared to cause the same 
side effects as indomethacin in pregnant women [68,70].
Several studies have found that low levels of indomethacin could 
be detected in breast milk in mothers that received up to 300 mg 
daily, but no side effects have been reported in breastfed infants 
[68]. Indomethacin is also administrated directly to infants for ther-
apeutic purposes, for example, to treat patent ductus arteriosus in 
the newborn.
HEMICR ANIA CONTINUA
Patients with hemicrania continua generally show a complete re-
sponse to therapeutic doses of indomethacin. For patients who 
cannot tolerate indomethacin, other options include COX inhibitors, 
melatonin, gabapentin, verapamil, topiramate, greater occipital 
nerve blocks, onabotulinumtoxin injections, and occipital nerve 
stimulation [2,71]. The efficacies of these treatments are poorly 
documented [66]. Hemicrania continua during pregnancy and lacta-
tion is managed with the same approaches described for paroxysmal 
hemicrania.
SUNC T/SUNA SYNDROME
Attacks of SUNCT/SUNA are so short that acute drugs cannot pro-
vide benefit. Consequently, the main treatment is prophylactic la-
motrigine [72]. The second choice is gabapentin or topiramate [66]. 
However, lamotrigine or gabapentin should be preferred during 
pregnancy. Lamotrigine treatment during pregnancy has been ex-
tensively studied. For prepregnancy doses below 325 mg/day it has 
shown a good safety profile regarding congenital malformations. In 
addition, long- term cognitive outcome in children exposed in utero 
does not seem to be affected [31]. During pregnancy, most women 
require an increase in the dose to avoid treatment failure [31]. To 
avoid toxicity, the dose must be reduced to prepregnancy levels 
over the first 2– 3 weeks after delivery [73]. Lamotrigine passes into 
breast milk in significant amounts. Several studies have reported ad-
verse drug reactions in breastfed neonates when the maternal dose 
was not reduced post partum. Risks are particularly high when the 
infant is premature, underweight or ill [15].
CONCLUSION
The choice of TAC treatment for women in childbearing age, and in 
pregnant and breastfeeding women can be a challenge. The clinician 
must often choose between treatment options with good efficacy 
but scarce safety documentation, and those with less documented 
efficacy but better safety profiles. The medical decisions must rest 
on thoroughly informed and documented consent. Pregnancy plan-
ning should start early in women of childbearing age with TACs. The 
safety of each drug varies for the different trimesters. Most treat-
ment options are compatible with breastfeeding. Due to the debili-
tating nature of TACs, effective treatment is important both during 
pregnancy and lactation. Tapering off prophylactic drugs due to 
pregnancy plans can leave some women severely disabled. In our 
experience, this can potentially result in an increase in rescue drug 
use, stress, inadequate nutrition, social deprivation, and depressive 
symptoms. Moreover, these factors can adversely influence the 
course of pregnancy. Due to the disabling nature of TACs, these pa-
tients require clinical attention before, during, and after pregnancy. 
In addition, they often require a multidisciplinary approach.
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